Editas Medicine Inc
NASDAQ:EDIT
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.9801
4.15
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
ROIC
Return on Invested Capital
ROIC, or Return on Invested Capital, tells you how good a company is at turning its invested money into profits. In simple terms, ROIC shows how many dollars of profit the company makes for each dollar it has invested. A higher ROIC usually means the company is using its money wisely to grow and make more profits, which is a good sign for investors.
ROIC Across Competitors
| Country | Company | Market Cap | ROIC | ||
|---|---|---|---|---|---|
| US |
|
Editas Medicine Inc
NASDAQ:EDIT
|
223.8m USD |
-289%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
3 093%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
400.9B USD |
28%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
176.1B USD |
15%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
154.4B USD |
19%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.9B USD |
25%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-182%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.8B USD |
12%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
84.8B AUD |
10%
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
45B EUR |
62%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
53.3B USD |
-21%
|
Editas Medicine Inc
Glance View
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 264 full-time employees. The company went IPO on 2016-02-03. The firm is focused on developing transformative gene editing medicines to treat a range of serious diseases. The company has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The firm is focused on both in vivo gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and ex vivo gene-edited cell medicines, in which cells are edited with its technology. The firm's gene editing medicine programs include EDIT-101, EDIT-102, EDIT-103, EDIT-301 and EDIT-202.
See Also
ROIC, or Return on Invested Capital, tells you how good a company is at turning its invested money into profits. In simple terms, ROIC shows how many dollars of profit the company makes for each dollar it has invested. A higher ROIC usually means the company is using its money wisely to grow and make more profits, which is a good sign for investors.
Based on Editas Medicine Inc's most recent financial statements, the company has ROIC of -288.6%.